Have a feature idea you'd love to see implemented?
Let us know!
CLPT ClearPoint Neuro Inc
Price (delayed)
$12.58
Market cap
$347.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$328.11M
ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of
Highlights
ClearPoint Neuro's revenue has increased by 29% YoY and by 7% from the previous quarter
The gross profit has grown by 26% YoY and by 12% from the previous quarter
The equity has grown by 17% YoY but it has contracted by 7% from the previous quarter
The gross margin has grown by 4.7% from the previous quarter but it has contracted by 2.9% YoY
The quick ratio has plunged by 54% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of CLPT
Market
Valuations
Earnings
Shares outstanding
27.6M
Market cap
$347.15M
Enterprise value
$328.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
10.74
Price to sales (P/S)
12.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.69
Revenue
$28.07M
EBIT
-$18.17M
EBITDA
-$16.39M
Free cash flow
-$9.9M
Per share
Balance sheet
Liquidity
EPS
-$0.7
Free cash flow per share
-$0.36
Book value per share
$1.17
Revenue per share
$1.02
TBVPS
$1.88
Total assets
$52.57M
Total liabilities
$20.44M
Debt
$13.8M
Equity
$32.13M
Working capital
$29.86M
Debt to equity
0.43
Current ratio
2.79
Quick ratio
2.18
Net debt/EBITDA
1.16
Margins
Efficiency
Dividend
EBITDA margin
-58.4%
Gross margin
59.8%
Net margin
-64.1%
Operating margin
-66.2%
Return on assets
-37.3%
Return on equity
-64.2%
Return on invested capital
-87.7%
Return on capital employed
-50.6%
Return on sales
-64.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLPT stock price
How has the ClearPoint Neuro stock price performed over time
Intraday
2.36%
1 week
4.31%
1 month
10.35%
1 year
135.14%
YTD
85.27%
QTD
12.22%
Financial performance
How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$28.07M
Gross profit
$16.8M
Operating income
-$18.57M
Net income
-$17.98M
Gross margin
59.8%
Net margin
-64.1%
CLPT's net margin is up by 33% YoY and by 19% QoQ
ClearPoint Neuro's operating margin has increased by 32% YoY and by 17% from the previous quarter
ClearPoint Neuro's revenue has increased by 29% YoY and by 7% from the previous quarter
The gross profit has grown by 26% YoY and by 12% from the previous quarter
Growth
What is ClearPoint Neuro's growth rate over time
Valuation
What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
10.74
P/S
12.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.69
ClearPoint Neuro's EPS has increased by 18% YoY and by 16% from the previous quarter
The P/B is 88% above the last 4 quarters average of 5.7 but 76% below the 5-year quarterly average of 45.2
The equity has grown by 17% YoY but it has contracted by 7% from the previous quarter
The price to sales (P/S) is 102% higher than the last 4 quarters average of 6.1
ClearPoint Neuro's revenue has increased by 29% YoY and by 7% from the previous quarter
Efficiency
How efficient is ClearPoint Neuro business performance
ClearPoint Neuro's return on invested capital has decreased by 42% YoY
ClearPoint Neuro's ROS has increased by 33% YoY and by 19% from the previous quarter
The return on equity has grown by 17% since the previous quarter but it has declined by 5% year-on-year
CLPT's ROA is up by 15% from the previous quarter and by 6% YoY
Dividends
What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLPT.
Financial health
How did ClearPoint Neuro financials performed over time
The company's total assets is 157% higher than its total liabilities
The current ratio has plunged by 57% YoY and by 11% from the previous quarter
The quick ratio has plunged by 54% YoY and by 13% from the previous quarter
CLPT's debt is 57% lower than its equity
The equity has grown by 17% YoY but it has contracted by 7% from the previous quarter
The debt to equity has declined by 17% year-on-year but it has increased by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.